These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 25406566)

  • 1. [FLT3 inhibitor monotherapy for refractory acute myeloid leukemia: a case report].
    Pan J; Yang JF; Tong CR
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 Nov; 16(11):1168-9. PubMed ID: 25406566
    [No Abstract]   [Full Text] [Related]  

  • 2. FLT3 inhibitors in acute myeloid leukemia.
    el-Shami K; Stone RM; Smith BD
    Expert Rev Hematol; 2008 Dec; 1(2):153-60. PubMed ID: 21082920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FLT3 inhibitors for acute myeloid leukemia.
    Lancet JE
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):573-5. PubMed ID: 26452187
    [No Abstract]   [Full Text] [Related]  

  • 4. Lestaurtinib: a multi-targeted FLT3 inhibitor.
    Fathi AT; Levis M
    Expert Rev Hematol; 2009 Feb; 2(1):17-26. PubMed ID: 21082990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: evidence of efficacy continues to mount.
    Fesler MJ; Richart JM; Petruska PJ
    Leuk Res; 2010 Oct; 34(10):e268-9. PubMed ID: 20417967
    [No Abstract]   [Full Text] [Related]  

  • 6. The clinical development of FLT3 inhibitors in acute myeloid leukemia.
    Knapper S
    Expert Opin Investig Drugs; 2011 Oct; 20(10):1377-95. PubMed ID: 21895538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FLT3 inhibitors in acute myeloid leukemia: increasing options.
    Kadia TM
    Clin Adv Hematol Oncol; 2021 Jun; 19(6):352-355. PubMed ID: 34106908
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of quizartinib in the treatment of acute myeloid leukemia.
    Ostronoff F; Estey E
    Expert Opin Investig Drugs; 2013 Dec; 22(12):1659-69. PubMed ID: 24070241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [FLT3 inhibitors for acute myeloid leukemia].
    Kiyoi H
    Nihon Rinsho; 2014 Jun; 72(6):1035-41. PubMed ID: 25016800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report.
    Winkler J; Rech D; Kallert S; Rech J; Meidenbauer N; Roesler W; Mackensen A
    Leuk Res; 2010 Oct; 34(10):e270-2. PubMed ID: 20627386
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel targeted therapy for acute myeloid leukemia with a dual FLT3 and JAK2 inhibitor.
    Lou YJ
    Acta Pharmacol Sin; 2012 Feb; 33(2):212-3. PubMed ID: 22231396
    [No Abstract]   [Full Text] [Related]  

  • 12. Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study.
    Shah NP; Talpaz M; Deininger MW; Mauro MJ; Flinn IW; Bixby D; Lustgarten S; Gozgit JM; Clackson T; Turner CD; Haluska FG; Kantarjian H; Cortes JE
    Br J Haematol; 2013 Aug; 162(4):548-52. PubMed ID: 23691988
    [No Abstract]   [Full Text] [Related]  

  • 13. FLT3 inhibitors for the treatment of acute myeloid leukemia.
    Wiernik PH
    Clin Adv Hematol Oncol; 2010 Jun; 8(6):429-36, 444. PubMed ID: 20733555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice.
    Nordigården A; Zetterblad J; Trinks C; Gréen H; Eliasson P; Druid P; Lotfi K; Rönnstrand L; Walz TM; Jönsson JI
    Br J Haematol; 2011 Oct; 155(2):198-208. PubMed ID: 21848891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FLT3 Inhibitor-Associated Neutrophilic Dermatoses.
    Varadarajan N; Boni A; Elder DE; Bagg A; Micheletti R; Perl AE; Rosenbach M
    JAMA Dermatol; 2016 Apr; 152(4):480-2. PubMed ID: 26886840
    [No Abstract]   [Full Text] [Related]  

  • 16. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
    Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
    Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3,4-Diarylmaleimides-a novel class of kinase inhibitors-effectively induce apoptosis in FLT3-ITD-dependent cells.
    Heidel FH; Mack TS; Razumovskaya E; Blum MC; Lipka DB; Ballaschk A; Kramb JP; Plutizki S; Rönnstrand L; Dannhardt G; Fischer T
    Ann Hematol; 2012 Mar; 91(3):331-44. PubMed ID: 21881825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A substrate peptide for the FLT3 receptor tyrosine kinase.
    Böhmer FD; Uecker A
    Br J Haematol; 2009 Jan; 144(1):127-30. PubMed ID: 19016738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
    Lin WH; Hsu JT; Hsieh SY; Chen CT; Song JS; Yen SC; Hsu T; Lu CT; Chen CH; Chou LH; Yang YN; Chiu CH; Chen CP; Tseng YJ; Yen KJ; Yeh CF; Chao YS; Yeh TK; Jiaang WT
    Bioorg Med Chem; 2013 Jun; 21(11):2856-67. PubMed ID: 23618709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.